TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
Journal
Blood
Journal Volume
118
Journal Issue
14
Pages
3803-3810
Date Issued
2011
Author(s)
Liu C.-Y.
Kuo Y.-Y.
Lee M.-C.
Chang Y.-C.
Kuo Y.-Y.
Lee F.-Y.
Liu M.-C.
Liu C.-W.
Tseng M.-H.
Huang C.-F.
Abstract
The studies concerning clinical implications of TET2 mutation in patients with primary acute myeloid leukemia (AML) are scarce. We analyzed TET2 mutation in 486 adult patients with primary AML. TET2 mutation occurred in 13.2% of our patients and was closely associated with older age, higher white blood cell and blast counts, lower platelet numbers, normal karyotype, intermediate-risk cytogenetics, isolated trisomy 8, NPM1 mutation, and ASXL1 mutation but mutually exclusive with IDH mutation. TET2 mutation is an unfavorable prognostic factor in patients with intermediate-risk cytogenetics, and its negative impact was further enhanced when the mutation was combined with FLT3-ITD, NPM1-wild, or unfavorable genotypes (other than NPM1+/FLT3-ITD- or CEBPA+). A scoring system integrating TET2 mutation with FLT3-ITD, NPM1, and CEBPA mutations could well separate AML patients with intermediate-risk cytogenetics into 4 groups with different prognoses (P < .0001). Sequential analysis revealed that TET2 mutation detected at diagnosis was frequently lost at relapse; rarely, the mutation was acquired at relapse in those without TET2 mutation at diagnosis. In conclusion, TET2 mutation is associated with poor prognosis in AML patients with intermediate-risk cytogenetics, especially when it is combined with other adverse molecular markers. TET2 mutation appeared to be unstable during disease evolution. ? 2011 by The American Society of Hematology.
SDGs
Other Subjects
additional sex comb like 1 protein; antineoplastic agent; CD135 antigen; CD14 antigen; CD56 antigen; CEBPA protein; isocitrate dehydrogenase; lactate dehydrogenase; mutant protein; nucleophosmin; ten elevan translocation 2 protein; transcription factor RUNX1; tumor marker; unclassified drug; acute granulocytic leukemia; adolescent; adult; age; aged; article; blast cell; cancer chemotherapy; cancer patient; cancer survival; controlled study; cytogenetics; female; frameshift mutation; gene mutation; genetic association; genetic risk; human; human cell; human tissue; karyotype; lactate dehydrogenase blood level; leukemia cell; leukocyte count; low drug dose; major clinical study; male; missense mutation; nonsense mutation; priority journal; prognosis; promyelocytic leukemia; protein expression; single nucleotide polymorphism; thrombocyte count; trisomy 8; wild type
Type
journal article